Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00285688

Recruitment Status : Unknown

Verified August 2008 by Rajavithi Hospital.
Recruitment status was: Recruiting

First Posted : February 2, 2006

Last Update Posted : August 5, 2008

Sponsor:

Information provided by:

Rajavithi Hospital

Study Description

Brief Summary:

Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide. The gold standard for Helicobacter pylori eradication is composed of Proton-pump inhibitor/Ranitidine bismuth citrate + Amoxycillin + Metronidazole /Clarithromycin. In Thailand, clarithromycin resistant strains increased and led to treatment failure. Data on file at Rajavithi Hospital showed that metronidazole resistant H. pylori was about 50% and Clarithromycin resistant strains accounted for 8%. This molecular genetic study will be performed in patients presenting with dyspepsia, who had an indication for gastroscopic examination, to explore the incidence of antibiotic resistant Helicobacter pylori in Rajavithi Hospital, Thailand.

Condition or disease	Intervention/treatment
Dyspepsia	Procedure: gastroscopic examination

Detailed Description:

Genetic and Biomolecular factors determining clarithromycin resistance will be characterized.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	200 participants
Observational Model:	Case Control
Time Perspective:	Prospective
Official Title:	Antibiotic Resistance Helicobacter Pylori and Clarithromycin Resistance Mutation in Helicobacter Pylori in Rajavithi Hospital
Study Start Date :	June 2006
Estimated Study Completion Date :	December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics Genes and Gene Therapy Health Facilities Indigestion

Drug Information available for: Clarithromycin

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
1 Gastroscope positive for H. pylori and resistant to clarithromycin	Procedure: gastroscopic examination gastroscopic examination for tissue biopsy and real time PCR for gene study
2 Gastroscope positive for H. pylori and not resistant to clarithromycin	Procedure: gastroscopic examination gastroscopic examination for tissue biopsy and real time PCR for gene study

Outcome Measures

Primary Outcome Measures :

Incidence of H. pylori Clarithromycin resistance gene [ Time Frame: one year ]

Secondary Outcome Measures :

Characteristic of H. pylori clarithromycin resistant gene mutation [ Time Frame: one year ]

Biospecimen Retention: Samples With DNA

Gastric Biopsy tissue and H. pylori DNA

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	15 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Dydpepsia patient with gastroscopic examination

Criteria

Inclusion Criteria:

male or female with dyspepsia
age > 15 years
fulfil indication for gastroscopic examination
able to give informed consent

Exclusion Criteria:

contraindication for gastroscopic examination and biopsy

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285688

Locations

Layout table for location information

Thailand
Rajavithi Hospital	Recruiting
Ratchathewi, Bangkok, Thailand, 10400
Contact: Piyathida Harnsomboonrana, M.D. 6618423854 pboontee@yahoo.com

Sponsors and Collaborators

Rajavithi Hospital

Investigators

Layout table for investigator information

Principal Investigator:	Piyathida Harnsoomboon, MD	Rajavithi Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hansomburana P, Anantapanpong S, Sirinthornpunya S, Chuengyong K, Rojborwonwittaya J. Prevalence of single nucleotide mutation in clarithromycin resistant gene of Helicobacter pylori: a 32-months prospective study by using hybridization real time polymerase chain reaction. J Med Assoc Thai. 2012 Mar;95 Suppl 3:S28-35.

Layout table for additonal information

Responsible Party:	Dr Piyathida Harnsomburana, Biomolecular Research Center, Rajavithi hospital: Thailand
ClinicalTrials.gov Identifier:	NCT00285688 History of Changes
Other Study ID Numbers:	RH-CMR-002
First Posted:	February 2, 2006 Key Record Dates
Last Update Posted:	August 5, 2008
Last Verified:	August 2008

Keywords provided by Rajavithi Hospital:


H. Pylori, Clarithromycin resistant, gene

Additional relevant MeSH terms:

Layout table for MeSH terms

Dyspepsia Signs and Symptoms, Digestive Signs and Symptoms Anti-Bacterial Agents Clarithromycin Anti-Infective Agents	Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors

To Top